GlobeNewswire

Standard Dental Labs Acquires M&D Dental Arts; Announces December 1 Launch Target for Bridge AI Software
04/11/2026
Acquisition expected to double Orlando laboratory output; internally developed platform connects digital dentistry workflows and lays groundwork for AI-assisted restoration design ORLANDO, Fla., Nov. 04, 2026 (GLOBE [...]
Valneva to Report Nine-Month 2026 Consolidated Financial Results on November 24, 2026
04/11/2026
Lyon (France), November 4, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it will report its nine-month 2026 financial results on Tuesday, November 24, 2026. The [...]
Valneva publiera ses résultats financiers consolidés des neuf premiers mois de l’année le 24 novembre 2026
04/11/2026
Lyon (France), le 4 novembre 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins, a annoncé aujourd'hui qu’elle publiera ses résultats financiers des neuf premiers mois de l’année [...]
Virbac : Declaration of the number of shares and voting rights 10/2026
04/11/2026
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial [...]
Virbac : Déclaration d'actions et de droits de vote 10/2026
04/11/2026
DÉCLARATION D’ACTIONS ET DE DROITS DE VOTE Informations relatives au nombre total de droits de vote et au nombre d’actions composant le capital (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) [...]
Tessera Therapeutics to Present New Preclinical Data Supporting its In Vivo Sickle Cell Disease Program and In Vivo CAR-T Applications at the 68th American Society of Hematology Annual Meeting
04/11/2026
SOMERVILLE, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Tessera Therapeutics, Inc. (“Tessera”), a clinical-stage biotechnology company pioneering a new approach in genetic medicine known as Gene Writing™, today announced [...]
Zelluna ASA awarded NOK 15.6 million Research Council of Norway grant to further advance TCR-NK manufacturing
04/11/2026
Oslo, 4 November 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic “off-the-shelf” T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today announced that the [...]
Asgard Therapeutics announces publication in Immunity demonstrating induction of cancer-fighting tertiary lymphoid structures across seven tumor types – and will present new AT-108 biomarker data at SITC 2026
04/11/2026
Study in Immunity highlights Asgard's ability to generate potent immunogenic tertiary lymphoid structures (imgTLSs) solely by reprogramming tumor cells into antigen-presenting conventional type 1 dendritic cells (cDC1s [...]
Moleculin Announces Acceptance of Annamycin Data for Presentation at the 2026 American Society of Hematology (ASH) Annual Meeting
04/11/2026
First interim results from pivotal Phase 2/3 trial highlight encouraging remission rates in patients with relapsed or refractory AML HOUSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. (Nasdaq: MBRX) (“ [...]
Tangram Announces Oral Presentation of TGM-148 Preclinical Data Highlighting Context-Dependent Mechanism of Action at the American Society of Hematology (ASH) 2026 Annual Meeting
04/11/2026
TGM-148 enhances thrombin generation in impaired hemostasis No thrombotic safety signals at repeat toxicology doses in healthy non-human primates Phase 1 trial in healthy volunteers underway, with initial data [...]
Daré Bioscience to Present at Stifel’s 2026 Healthcare Conference
04/11/2026
SAN DIEGO, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world [...]
Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the 68th ASH Annual Meeting and Exposition
04/11/2026
First clinical data for sutacimig in Factor VII deficiency (FVIID) shows multi-fold accumulation of endogenous FVII(a) with shortening of prothrombin time after a single subcutaneous dose in initial participants of the [...]
Kura Oncology and Kyowa Kirin to Present First Ziftomenib-FLT3 Inhibitor Clinical Data at ASH 2026
04/11/2026
– Two oral presentations to feature first ziftomenib combination data with quizartinib in newly diagnosed and gilteritinib in relapsed/refractory NPM1/FLT3 co-mutated AML – – Longer-term Phase 1b data for ziftomenib [...]
Solu Therapeutics to Present Initial Phase 1 Results of STX-0712 and New Preclinical Data on STX-0640 in Two Oral Presentations at the 2026 ASH Annual Meeting
04/11/2026
BOSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Solu Therapeutics, a biotechnology company pioneering novel therapies to eliminate disease-driving cells in cancer and immunology, today announced that initial results from its [...]
Lyell Immunopharma Announces $80 Million Private Placement to Advance Ronde-Cel Toward Planned BLA Submission
04/11/2026
Investors include ARCH Venture Partners, Adage Capital Management LP, Caligan Partners LP, RTW Investments, a leading mutual fund and other new and existing institutional investors. Ronde-cel, a next-generation CD19/ [...]
Lakefront Biotherapeutics Announces Poster Presentation at the 2026 American Society of Hematology Meeting
04/11/2026
Gamgertamig data from ongoing Phase 1b studies suggest potential to retain remission after B cell reconstitution, maintained in the absence of background therapy for autoimmune cytopenias, consistent with an “immune [...]
CRISPR Therapeutics to Present Clinical Data from Zugo-cel in Large B-Cell Lymphoma at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition
04/11/2026
ZUG, Switzerland and BOSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that clinical data in patients with relapsed or refractory large B-cell lymphoma from the ongoing Phase 1 [...]
Agios to Highlight Strength and Differentiation of Rare Hematology Portfolio with New Clinical Data for Mitapivat in Sickle Cell Disease and AG-236 in Polycythemia Vera at ASH 2026
04/11/2026
14 abstracts accepted at ASH 2026, including three oral presentations featuring new data across mitapivat clinical programs New analyses from RISE UP Phase 3 trial of mitapivat in sickle cell disease show durable [...]
Lyell Immunopharma to Present Positive Updated Ronde-Cel Data in More than 80 Patients at ASH 2026 from PiNACLE Pivotal Trial in 3L+ and from Phase 1/2 2L Cohort in Patients with Relapsed/Refractory Large B-Cell Lymphoma
04/11/2026
Ronde-cel achieved a 91% overall response rate and 77% complete response rate; median progression-free survival not reached and estimated 6-month duration of complete response of 92% in 44 patients with 3L+ R/R LBCL in [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum